1932

Abstract

Globally, 240,000 infants are newly infected with HIV-1 each year and 3.2 million children are living with the infection. Combination antiretroviral therapy (cART) has reduced HIV-1-related disease and mortality in children but is not curative owing to the early generation of a latent reservoir of long-lived memory CD4+ T cells bearing replication-competent HIV-1 provirus integrated into cellular DNA. This review focuses on recent advances in our understanding of the establishment of HIV-1 persistence in children and how early initiation of cART in the setting of the developing infant immune system limits the formation of the long-lived latent CD4+ cell reservoir that remains a barrier to remission or cure.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-091114-111159
2016-01-14
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/med/67/1/annurev-med-091114-111159.html?itemId=/content/journals/10.1146/annurev-med-091114-111159&mimeType=html&fmt=ahah

Literature Cited

  1. 1. UNAIDS 2014. Children and pregnant women living with HIV The Gap Report. http://www.unaids.org/en/resources/documents/2014/childrenandpregnantwomenlivingwithhiv
  2. De Cock KM, Fowler MG, Mercier E. 2.  et al. 2000. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283:1175–82 [Google Scholar]
  3. 3. AIDSinfo 2015. Guidelines for the use of antiretroviral agents in pediatric HIV infection Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf
  4. Bryson YJ, Luzuriaga K, Sullivan JL. 4.  et al. 1992. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N. Engl. J. Med. 327:1246–47 [Google Scholar]
  5. Kourtis AP, Lee FK, Abrams EJ. 5.  et al. 2006. Mother-to-child transmission of HIV-1: timing and implications for prevention. Lancet Infect. Dis. 6:726–32 [Google Scholar]
  6. Rouzioux C, Costagliola D, Burgard M. 6.  et al. 1995. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am. J. Epidemiol. 142:1330–37 [Google Scholar]
  7. 7. The European Collaborative Study 1994. Natural history of vertically acquired human immunodeficiency virus-1 infection. Pediatrics 94:815–19 [Google Scholar]
  8. Barnhart HX, Caldwell MB, Thomas P. 8.  et al. 1996. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics 97:710–16 [Google Scholar]
  9. Becquet R, Marston M, Dabis F. 9.  et al. 2012. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS ONE 7:e28510 [Google Scholar]
  10. Newell ML, Coovadia H, Cortina-Borja M. 10.  et al. 2004. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364:1236–43 [Google Scholar]
  11. Luzuriaga K, Wu H, McManus M. 11.  et al. 1999. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J. Virol. 73:362–67 [Google Scholar]
  12. Melvin AJ, Rodrigo AG, Mohan KM. 12.  et al. 1999. HIV-1 dynamics in children. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:468–73 [Google Scholar]
  13. Palumbo P, Wu H, Chadwick E. 13.  et al. 2007. Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J. Infect. Dis. 196:23–29 [Google Scholar]
  14. Richardson BA, Mbori-Ngacha D, Lavreys L. 14.  et al. 2003. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J. Virol. 77:7120–23 [Google Scholar]
  15. Shearer WT, Quinn TC, LaRussa P. 15.  et al. 1997. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336:1337–42 [Google Scholar]
  16. McIntosh K, Shevitz A, Zaknun D. 16.  et al. 1996. Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus. Pediatr. Infect. Dis. J. 15:1087–91 [Google Scholar]
  17. Blankson JN, Siliciano JD, Siliciano RF. 17.  2014. Finding a cure for human immunodeficiency virus-1 infection. Infect. Dis. Clin. North. Am. 28:633–50 [Google Scholar]
  18. Pan X, Baldauf HM, Keppler OT. 18.  et al. 2013. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes. Cell Res. 23:876–85 [Google Scholar]
  19. Bruner KM, Hosmane NN, Siliciano RF. 19.  2015. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 23:192–203 [Google Scholar]
  20. Chun TW, Carruth L, Finzi D. 20.  et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183–88 [Google Scholar]
  21. Persaud D, Pierson T, Ruff C. 21.  et al. 2000. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children. J. Clin. Invest. 105:995–1003 [Google Scholar]
  22. Luzuriaga K, Bryson Y, Krogstad P. 22.  et al. 1997. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336:1343–49 [Google Scholar]
  23. Persaud D, Palumbo PE, Ziemniak C. 23.  et al. 2012. Dynamics of the resting CD4+ T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 26:1483–90 [Google Scholar]
  24. Luzuriaga K, McManus M, Mofenson L. 24.  et al. 2004. A trial of three antiretroviral regimens in HIV-1-infected children. N. Engl. J. Med. 350:2471–80 [Google Scholar]
  25. Zanchetta M, Anselmi A, Vendrame D. 25.  et al. 2008. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir. Ther. 13:47–55 [Google Scholar]
  26. Luzuriaga K, Holmes D, Hereema A. 26.  et al. 1995. HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J. Immunol. 154:433–43 [Google Scholar]
  27. Pikora CA, Sullivan JL, Panicali D. 27.  et al. 1997. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J. Exp. Med. 185:1153–61 [Google Scholar]
  28. Huang S, Dunkley-Thompson J, Tang Y. 28.  et al. 2008. Deficiency of HIV-Gag-specific T cells in early childhood correlates with poor viral containment. J. Immunol. 181:8103–11 [Google Scholar]
  29. Luzuriaga K, McQuilken P, Alimenti A. 29.  et al. 1993. Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J. Infect. Dis. 167:1008–13 [Google Scholar]
  30. Thobakgale CF, Ramduth D, Reddy S. 30.  et al. 2007. Human immunodeficiency virus-specific CD8+ T-cell activity is detectable from birth in the majority of in utero-infected infants. J. Virol. 81:12775–84 [Google Scholar]
  31. Gibson L, Barysauskas CM, McManus M. 31.  et al. 2015. Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection. J. Clin. Immunol. 35:289–301 [Google Scholar]
  32. Ramduth D, Thobakgale CF, Mkhwanazi NP. 32.  et al. 2008. Detection of HIV type 1 gag-specific CD4+ T cell responses in acutely infected infants. AIDS Res. Hum. Retrovir. 24:265–70 [Google Scholar]
  33. Scott ZA, Beaumier CM, Sharkey M. 33.  et al. 2003. HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children. J. Immunol. 170:5786–92 [Google Scholar]
  34. Hartigan-O'Connor DJ, Abel K, McCune JM. 34.  2007. Suppression of SIV-specific CD4 +T cells by infant but not adult macaque regulatory T cells: implications for SIV disease progression. J. Exp. Med. 204:2679–92 [Google Scholar]
  35. Goo L, Chohan V, Nduati R. 35.  et al. 2014. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat. Med. 20:655–58 [Google Scholar]
  36. Pugatch D, Sullivan JL, Pikora CA. 36.  et al. 1997. Delayed generation of antibodies mediating human immunodeficiency virus type 1-specific antibody-dependent cellular cytotoxicity in vertically infected infants. Women and Infants Transmission Study Group. J. Infect. Dis. 176:643–48 [Google Scholar]
  37. Chadwick EG, Yogev R, Alvero CG. 37.  et al. 2011. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 25:643–49 [Google Scholar]
  38. Luzuriaga K, McManus M, Catalina M. 38.  et al. 2000. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses. J. Virol. 74:6984–91 [Google Scholar]
  39. Hainaut M, Peltier CA, Goetghebuer T. 39.  et al. 2005. Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event. Clin. Infect. Dis. 41:1820–21 [Google Scholar]
  40. Violari A, Cotton MF, Gibb DM. 40.  et al. 2008. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359:2233–44 [Google Scholar]
  41. 41. World Health Organization 2013. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. http://www.who.int/hiv/pub/guidelines/arv2013/download/en/
  42. 42. World Health Organization 2014. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/
  43. 43. AIDSinfo 2015. Guidelines for the use of antiretroviral agents in pediatric HIV infection Clinical Guidelines Portal. https://aidsinfo.nih.gov/guidelines/html/2/pediatric-arv-guidelines/0
  44. Besson GJ, Lalama CM, Bosch RJ. 44.  et al. 2014. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin. Infect. Dis. 59:1312–21 [Google Scholar]
  45. Luzuriaga K. 45.  2014. Impact of early ART on HIV eradication in children Presented at Conf. Retrovir. Opportunistic Infect., 21st, Boston, MA, Mar 3–6
  46. Buzon MJ, Martin-Gayo E, Pereyra F. 46.  et al. 2014. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J. Virol. 88:10056–65 [Google Scholar]
  47. Koelsch KK, Liu L, Haubrich R. 47.  et al. 2008. Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J. Infect. Dis. 197:411–19 [Google Scholar]
  48. Strain MC, Little SJ, Daar ES. 48.  et al. 2005. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J. Infect. Dis. 191:1410–18 [Google Scholar]
  49. Uprety P, Chadwick EG, Rainwater-Lovett K. 49.  et al. 2015. Cell-associated HIV-1 DNA and RNA decay dynamics during early combination antiretroviral therapy in HIV-1-infected infants. Clin. Infect. Dis. In press. doi: 10.1093/cid/civ688
  50. Chun TW, Justement JS, Murray D. 50.  et al. 2010. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24:2803–8 [Google Scholar]
  51. Hocqueloux L, Avettand-Fenoel V, Jacquot S. 51.  et al. 2013. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J. Antimicrob. Chemother. 68:1169–78 [Google Scholar]
  52. Saez-Cirion A, Bacchus C, Hocqueloux L. 52.  et al. 2013. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI Study.. PLoS Pathog. 9:e1003211 [Google Scholar]
  53. Persaud D, Ray SC, Kajdas J. 53.  et al. 2007. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res. Hum. Retrovir. 23:381–90 [Google Scholar]
  54. Crooks AM, Bateson R, Cope AB. 54.  et al. 2015. Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies. J. Infect. Dis. 2121361–65
  55. Siliciano JD, Kajdas J, Finzi D. 55.  et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727–28 [Google Scholar]
  56. Zanchetta M, Walker S, Burighel N. 56.  et al. 2006. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy. J. Infect. Dis. 193:1718–27 [Google Scholar]
  57. Luzuriaga K, Tabak B, Garber M. 57.  et al. 2014. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J. Infect. Dis. 210:1529–38 [Google Scholar]
  58. Chomont N, El-Far M, Ancuta P. 58.  et al. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15:893–900 [Google Scholar]
  59. Ananworanich J, Puthanakit T, Suntarattiwong P. 59.  et al. 2014. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS 28:1015–20 [Google Scholar]
  60. van Zyl GU, Bedison MA, van Rensburg AJ. 60.  et al. 2015. Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. J. Infect. Dis. 212:39–43 [Google Scholar]
  61. Persaud D, Patel K, Karalius B. 61.  et al. 2014. Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents. JAMA Pediatr. 168:1138–46 [Google Scholar]
  62. Buzon MJ, Sun H, Li C. 62.  et al. 2014. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20:139–42 [Google Scholar]
  63. Goujard C, Girault I, Rouzioux C. 63.  et al. 2012. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir. Ther. 17:1001–9 [Google Scholar]
  64. Fauci AS, Marston HD, Folkers GK. 64.  2014. An HIV cure: feasibility, discovery, and implementation. JAMA 312:335–36 [Google Scholar]
  65. Rainwater-Lovett K, Luzuriaga K, Persaud D. 65.  2015. Very early combination antiretroviral therapy in infants: prospects for cure. Curr. Opin. HIV AIDS 10:4–11 [Google Scholar]
  66. Hill AL, Rosenbloom DI, Fu F. 66.  et al. 2014. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. PNAS 111:13475–80 Erratum. 2014 PNAS 111:5598 [Google Scholar]
  67. Persaud D, Gay H, Ziemniak C. 67.  et al. 2013. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369:1828–35 [Google Scholar]
  68. Luzuriaga K, Gay H, Ziemniak C. 68.  et al. 2015. Viremic relapse after HIV-1 remission in a perinatally infected child. N. Engl. J. Med. 372:786–88 [Google Scholar]
  69. Bitnun A, Samson L, Chun TW. 69.  et al. 2014. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin. Infect. Dis. 59:1012–19 [Google Scholar]
  70. Butler KM, Gavin P, Coughlan S. 70.  et al. 2015. Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth. Pediatr. Infect. Dis. J. 34:e48–51 [Google Scholar]
  71. Giacomet V, Trabattoni D, Zanchetta N. 71.  et al. 2014. No cure of HIV infection in a child despite early treatment and apparent viral clearance. Lancet 384:1320 [Google Scholar]
  72. Persaud D, Deveikis A, Gay H. 72.  et al. 2014. Very early combination antiretroviral therapy in perinatal HIV infection: two case studies Presented at Conf. Retrovir. Opportunistic Infect., 21st, Boston, MA, Mar 3–6
  73. Brophy J, Chun TW, Samson L. 73.  2014. Impact of early initiation of combination antiretroviral therapy on measures of virus in peripheral blood of vertically HIV-1 infected children Presented at Int. AIDS Conf., 20th, Melbourne, Australia, Jul 19–25
  74. Ho YC, Shan L, Hosmane NN. 74.  et al. 2013. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155:540–51 [Google Scholar]
  75. Whitney JB, Hill AL, Sanisetty S. 75.  et al. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512:74–77 [Google Scholar]
  76. Klein N, Palma P, Luzuriaga K. 76.  et al. 2015. Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission. Lancet Infect. Dis. 151108–14
  77. Barouch DH, Deeks SG. 77.  2014. Immunologic strategies for HIV-1 remission and eradication. Science 345:169–74 [Google Scholar]
  78. Archin NM, Sung JM, Garrido C. 78.  et al. 2014. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12:750–64 [Google Scholar]
  79. Tebas P, Stein D, Tang WW. 79.  et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370:901–10 [Google Scholar]
  80. Saayman S, Ali SA, Morris KV. 80.  et al. 2015. The therapeutic application of CRISPR/Cas9 technologies for HIV. Expert Opin. Biol. Ther. 15:819–30 [Google Scholar]
  81. Hutter G, Nowak D, Mossner M. 81.  et al. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360:692–98 [Google Scholar]
  82. Yukl SA, Boritz E, Busch M. 82.  et al. 2013. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9:e1003347 [Google Scholar]
  83. Henrich TJ, Hanhauser E, Marty FM. 83.  et al. 2014. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann. Intern. Med. 161:319–27 [Google Scholar]
/content/journals/10.1146/annurev-med-091114-111159
Loading
/content/journals/10.1146/annurev-med-091114-111159
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error